Exhibit 99.1

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis (OA). The six-month follow-up has now been completed for all patients. The results re-affirm the three-month data reported previously and substantiate the identification of an age-related primary OA responder population.

Summary of the 6-month Topline Data

Professor Philip Conaghan, MBBS, PhD, FRACP, FRCP, is an internationally renowned leader in osteoarthritis and musculoskeletal imaging, and the Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Prof. Conaghan has authored more than 700 publications and chaired multiple global guidelines and trial initiatives and is a member of the Clinical Advisory Board of Enlivex.

Prof. Conaghan commented “The toll of knee osteoarthritis continues to grow with the increasing burden of aging and obesity, and subsequently the need for effective therapies is becoming a major need undertaking. With the understanding that inflammatory mediators play a central role in the progression of knee pain and dysfunction, new treatment strategies can be proposed. I am encouraged by the results demonstrated in the study so far and continue to follow the clinical development of Allocetra™ as an immune modulating agent that could potentially pioneer a new therapeutic approach.”

Oren Hershkovitz, Ph.D., CEO of Enlivex, stated: “We believe the six-month results provide strong evidence that Allocetra™ delivers a durable and clinically meaningful benefit for patients with age-related primary knee osteoarthritis. A single treatment cycle producing at least six months of sustained efficacy represents not only a potentially transformative therapeutic option for patients but also supports a compelling and scalable commercial opportunity for Enlivex.”

Einat Galamidi, M.D., CMO of Enlivex, added: “We are highly encouraged by the durable clinical improvements observed in this patient population. These results pave the way for our upcoming Phase IIb trial evaluating Allocetra™ in age-related primary knee osteoarthritis. We plan to initiate this study in the first half of 2026 and are committed to advancing Allocetra™ as a potential novel treatment to improve the quality of life for millions of patients affected by knee osteoarthritis.”

In-depth analysis of the 6-month results is provided in a separate presentation, available as part of the Companiy’s SEC filings and can be downloaded from its website.

About ENX-CL-05-001

ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisted of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen or the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial’s key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. 

ABOUT KNEE OSTEOARTHRITIS

Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.

Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT

IR Contact:

KCSA Strategic Communications
Jack Perkins
Enlivex@KCSA.com

Exhibit 99.2

Nasdaq: ENLV ENLIVEX CLINICAL DEVELOPMENT November 2025

FORWARD - LOOKING STATEMENTS 2 | Nasdaq: ENLV These slides and the accompanying oral presentation contain forward - looking statements and information. Forward - looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may”, “might”, “will”, “should”, “could”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “intend”, “future”, “potential” or “continue”, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward - looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward - looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward - looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward - looking statement, whether as a result of new information, future events or otherwise, except as required by law. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of our securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, any of our securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors.

MACROPHAGE MODULATION FOR THE TREATMENT OF INFLAMMATORY DISEASES Novel therapeutic modality: macrophage modulation. Cost - effective cell therapy: simple manufacturing process yielding a ready - to - use off - the - shelf cell therapy. Substantial market: unmet need in inflammatory and autoimmune diseases. Novel approach: allogeneic cells to trigger macrophage reprogramming. ON OFF A Enlivex is a clinical stage pharmaceutical company developing Allocetra , a universal, off - the - shelf cell therapy designed to reprogram macrophages into their homeostatic state, for treatment of inflammatory diseases .

About: 3 | Nasdaq: ENLV A Allocetra macrophage CELLULAR FIRST RESPONDERS: MACROPHAGES AND THEIR CRITICAL ROLE IN INFLAMMATION Recruit other immune cells Defend against pathogens Cleanup senescent or dead cells Control tissue homeostasis and repair Antigen presentation Cytokine secretion Phagocytosis Immunomodulation Regulation Resolution and homeostasis Macrophages orchestrate inflammation and its resolution. Enlivex's Allocetra mechanism Initiation ON Macrophages, which are found in abundance throughout the body, are immune cells that reside in or infiltrate human tissue. Main functions: Role in inflammation: 2 3 1 T 4 | Nasdaq: ENLV T T The current understanding among researchers is that disrupted inflammatory processes form the basis of many diseases, beyond “classical” inflammatory diseases.

PROMOTING BALANCE: APOPTOTIC CELLS FACILITATE MACROPHAGE HOMEOSTASIS MACROPHAGE Eat me TSP - 1 PtdSer TAM AMP The interaction between apoptotic cells and macrophages contributes to the pro - resolution and immune - modulating effects of Allocetra , promoting macrophage and immune homeostasis. How apoptotic cells influence macrophages APOPTOTIC CELL NF - kB TLR inflammasome Tolerate me Calm down Apoptotic Cells Induce NF - kB and Inflammasome Negative Signaling Amir Grau, Adi Tabib, Inna Grau, Inna Reiner, Dror Mevorach PLOS One, 2015 Apoptotic Cells induced Signaling for immune Homeostasis in Macrophages and Dendritic Cells Uriel Trahtemberg and Dror Mevorach Frontiers in immunology, 2017 Prof. Dror Mevorach Scientific Founder Enlivex's Allocetra mechanism 5 | Nasdaq: ENLV ALLOCETRA : AN OFF THE SHELF CELL THERAPY DESIGNED TO RESTORE MACROPHAGE HOMEOSTASIS PtdSer Apoptotic cell • harnesses the same biological activity seen in naturally occurring apoptotic cells; • presents a highly - differentiated, off - the - shelf, cellular therapy modality.

Allocetra Allogeneic mononuclear cells collected from healthy donors induced to a stable apoptotic state. collect cells from healthy donors proprietary apoptotic cell modification process cells express “eat me” signal cells are frozen off the shelf, cost effective cell therapy Process: 1. Patient with systemic or joint inflammation 2. Allocetra cells are injected into the patient 3. Allocetra cells are engulfed by macrophages 6 | Nasdaq: ENLV 4 .

Macrophage homeostasis is restored Mechanism: Eat me A A A A A A A T T T A Indication Pre - clinical Phase I/II Phase II Phase III Administration Randomized, controlled, Phase II, 120 patients Efficacy stage completed; safety follow - up completed Systemic administration ENX - CL - 02 - 002 NCT04612413 Organ failure associated with sepsis Study # Sepsis Program - seeking for potential external collaboration or out - licensing, instead of pursuing internal development ALLOCETRA TM CURRENT PIPELINE: BUILDING MOMENTUM Open - label 6 patients, enrolling Local TMJ injection 1400 - 24 - SMC NCT06748651 Temporomandibular joint osteoarthritis Randomized/controlled, Expected initiation 149 patients, enrollment completed Q2 2026 Local knee injection ENX - CL - 05 - 001 NCT06233474 Moderate to severe knee osteoarthritis 7 | Nasdaq: ENLV ALLOCETRA FOR THE TREATMENT OF OSTEOARTHRITIS 8 | Nasdaq: ENLV

OSTEOARTHRITIS: A GROWING MARKET WITH SIGNIFICANT POTENTIAL 9 | Nasdaq: ENLV Standard of care Disease overview Disease manifestation: cartilage damage, abnormal bone remodeling, and inflammation of the synovium. Today 2023 2040 2030 32.5MM $6.8B 78MM $15.7B Market Lifestyle changes Physiotherapy Pain medication Surgery Market size 2 : Femur Synovitis Joint space narrowing Cartilage loss Subchondral bone cysts/ sclerosis Tibia Fibula U.S.

Cases 1 : 1 - Arthritis Foundation ( https://www.arthritis.org/ ) 2 - Verified Market Research reports MACROPHAGES ARE AN EMERGING NEW TARGET FOR OSTEOARTHRITIS TREATMENT 10 | Nasdaq: ENLV Synovial macrophages in osteoarthritis: the key to understanding pathogenesis? Amanda Thomson and Catharien M. U. Hilkens Frontiers in Immunology 2021 Imbalance of M1/M2 macrophages is linked to severity level of knee osteoarthritis. Baolong Liu, Maoquan Zhang, Jingming Zhao, Mei Zheng and Hao Yang Experimental and therapeutic medicine 2018 An emerging target in the battle against osteoarthritis: macrophage polarization. Yulong Sun, Zhuo Zuo and Yuanyuan Kuang International Journal of Molecular Sciences 2020 Characterizing heterogeneity in the response of synovial mesenchymal progenitor cells to synovial macrophages in normal individuals and patients with osteoarthritis. Akash Fichadiya, Karri L Bertram, Guomin Ren, Robin M Yates and Roman J Krawetz Journal of Inflammation 2016 The role of innate immunity in osteoarthritis : when our first line of defense goes on the offensive. Eric W.

Orlowsky and Virginia Byers Kraus The Journal of Rheumatology 2015 KNEE OSTEOARTHRITIS (KOA) MARKET • High prevalence & burden: • 32M Americans today; projected 78M by 2040 • One of the most disabling diseases globally • Unmet medical need: • No approved disease - modifying treatments • Current options: pain relief, steroids, surgery • Age - related progression: • Prevalence rises to 30% at age 60+ • 50% of KOA patients are 60+ • As individuals age, the cumulative effects of wear and tear on joint tissues become increasingly evident and induce low grade inflammation mainly mediated by resident macrophages and fibroblasts, and the regenerative capacity of cartilage diminishes • Future growth driver: • Rising geriatric population → increasing OA prevalence 0 10 20 30 40 50 60 30 – 39 40 – 49 50 – 59 60 – 69 70 – 79 80+ Prevalence (%) Age Group Prevalence of Osteoarthritis increases with age 1 Men (%) Women (%) Total (%) 11 | 1 Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population - based studies, A. Cui et al. / EClinicalMedicine 2930 (2020) 100587 RESULTS FROM THE COMPLETED ENX - CL - 05 - 001 – PHASE IIa IN PATIENTS WITH SYMPTOMATIC MODERATE TO SEVERE KNEE OA 12 |

ENX - CL - 05 - 001 – PHASE IIa STUDY DESIGNED A PRIORI TO IDENTIFY CORRELATION OF TREATMENT EFFECT AND BASELINE FACTORS Key baseline covariates to be examined in the study Inflammation Pain Other covariates BMI Heterogeneous patient population included indiscriminately Purpose was to assess safety, efficacy, and potentially find a strong signal in a responder sub - population to guide future development (As stated in our 2024 annual report/PR) Phase IIa is the proper clinical stage to find the responder sub - population “OA is a clinical syndrome and not a singular molecular disease” OA leading experts forewarned us prior to study design 13 | ENX - CL - 05 - 001 – PHASE IIa OBJECTIVES MET: Specific responder profile • More than ~50% of the patients in the study • Representing more than ~50% of the KOA market • Aligned with the proposed mechanism of action of Allocetra TM (a) FAVORABLE SAFETY PROFILE & POSITIVE EFFECT, (b) HIGH RESPONDERS WERE IDENTIFIED (REPRESENTING 50% OF THE KOA MARKET) • We had clear success in isolating the key molecular disease for which our drug works well • This finding directly illustrates that our hypotheses were correct – due to the heterogeneity of the patient population, a distinct responder group needs to be identified 14 |

ENX - CL - 05 - 001 KNEE - OSTEOARTHRITIS PHASE IIa RESULTS - 3 & 6 - MONTH TOPLINE DATA ANALYSIS 15 | Patient criteria • Patients with symptomatic moderate to severe knee OA who have failed to respond to conventional OA therapy; • Age 45 - 80 years; • Kellgren - Lawrence (K - L) Grade 2 or 3.

ClinicalTrials.gov Registration: NCT06233474 NRS=numerical rating scale. WOMAC= Standard knee questionnaire evaluating pain, stiffness & physical function ENX - CL - 05 - 001: PHASE I/IIa 2 - stage trial design - randomized, double - blind, placebo - controlled, multi - country study Endpoints Primary Safety and tolerability. Secondary Change in pain and function assessments (NRS, WOMAC) Timepoints Efficacy: 3 - month, 6 - month Safety: 12 - month follow - up Phase IIa: Randomized, double - blind, placebo - controlled 134 patients 3 injections (in total) of Allocetra TM or Placebo, each injection 2 weeks from the previous injection Phase I: Dose escalation & safety 15 patients Independent safety committee no negative safety signal, highest dose selected for Phase IIa Efficacy objectives 16 | • Reduction in pain, increase in function and reduction in stiffness • Numerical grading based on the patients’ assessment using a questionnaire • The validated questionnaire is named WOMAC • Aligned with FDA’s accepted Phase III endpoints and timepoints Standardized Effect Size ≥65 ≥60 mITT Efficacy Endpoint NRS Pain Change from Baseline (scale 0 - 10) - 0.76 - 0.41 - 0.22 3 Months - 0.80 - 0.30 - 0.08 6 Months WOMAC Pain Change from Baseline (randomized 0 - 100) - 1.05 - 0.53 - 0.20 3 Months - 0.88 - 0.25 - 0.05 6 Months WOMAC Function Change from Baseline (randomized 0 - 100) - 1.22 - 0.67 - 0.21 3 Months - 1.22 - 0.48 - 0.15 6 Months WOMAC Total Change from Baseline (randomized 0 - 100) - 1.20 - 0.62 - 0.19 3 Months - 1.14 - 0.41 - 0.11 6 Months COMPETITIVE COMPARISON OF STANDARDIZED EFFECT SIZES Adapted from S. Westbrook presentation 0852 at ACR 2025 Allocetra TM 0.7 0.8 0.9 1.0 1.1 1.2 0.7 0.8 0.9 WOMAC (Pain) WOMAC (Function) 17 |

PAIN NRS WEEKLY CHANGE OVER TIME Placebo Allocetra Substantial and durable weekly pain NRS reduction compared to placebo, with increased effect trending with age.

18 | RESPONDER RATES (OMERACT - OARSI CRITERIA) – WOMAC PAIN 6m 3m Age threshold 58% 50% Placebo ≥ 60 65% 71% Allocetra 12% 41% % better than placebo 0.5604 0.0773 p - value 44% 37% Placebo ≥ 63 64% 68% Allocetra 45% 83% % better than placebo 0.1448 0.0219 p - value 38% 33% Placebo ≥ 65 63% 75% Allocetra 64% 125% % better than placebo 0.1069 0.0042 p - value Trending with age 19 | High responder rates compared to placebo, with increasing percentages trending with age Responders were defined as patients that met the OMERACT - OARSI criteria (Outcome Measures in Arthritis Clinical Trials - Osteoarthritis Research Society International)

ALLOCETRA EFFECT IN PRIMARY OA: CLINICALLY MEANINGFUL, STATISTICALLY SIGNIFICANT, TRENDING WITH AGE (REDUCTION IN PAIN) WOMAC pain change 3 months, Primary OA population WOMAC pain change, 3 months Age ≥ 65 (33% of patients) Allocetra n=23 Placebo n=19 Age ≥ 60 (54% of patients) Allocetra n=33 Placebo n=36 Age ≥ 63 (40% of patients) Allocetra n=27 Placebo n=25 Avg: - 9.16 20.3 Avg: - 9.6 20.4 Avg: - 29.0 17.9 Avg: - 27.8 20.8 Avg: - 16.2 22.5 Avg: - 27.2 20.1 Positive effect difference : 183% p - value = 0.0029 Positive effect difference : 217% p - value = 0.0017 Positive effect difference : 72% p - value = 0.030 Allocetra Placebo Note: baseline demographics & characteristics were well - balanced | Results are normalized to 0 - 100 scale 20 ALLOCETRA EFFECT IN PRIMARY OA: CLINICALLY MEANINGFUL, STATISTICALLY SIGNIFICANT, TRENDING WITH AGE (REDUCTION IN PAIN) WOMAC pain change 6 months, Primary OA population WOMAC pain change, 6 months Age ≥ 60 (52% of patients) Allocetra n=31 Placebo n=32 Age ≥ 65 (31% of patients) Allocetra n=21 Placebo n=17 Age ≥ 63 (39% of patients) Allocetra n=25 Placebo n=22 Avg: - 12.7 22.8 Avg: - 25.1 19.8 Avg: - 19.8 23.1 Avg: - 26.7 16.1 Avg: - 12.4 16.7 Avg: - 24.2 16.2 Positive effect difference : 94% p - value = 0.0422 Positive effect difference : 27% p - value = 0.3231 Positive effect difference : 115% p - value = 0.0110 Allocetra Placebo Note: baseline demographics & characteristics were well - balanced Results are normalized to 0 - 100 scale 21 |

ALLOCETRA EFFECT IN PRIMARY OA: CLINICALLY MEANINGFUL, STATISTICALLY SIGNIFICANT, TRENDING WITH AGE (REDUCTION IN PAIN & STIFFNESS, AND INCREASE IN FUNCTION) WOMAC total change 3 months, Primary OA population WOMAC pain change, 3 months Age ≥ 60 (54% of patients) Avg: - 26.4 20.3 Avg: - 13.8 20.5 Positive effect difference : 92% Allocetra n=33 Placebo n=36 Age ≥ 65 (33% of patients) Avg: - 27.1 16.5 Avg: - 6.03 18.9 Positive effect difference : 350% Allocetra n=23 Placebo n=19 Age ≥ 63 (40% of patients) Positive effect difference : 237% Avg: - 25.6 18.9 Avg: - 7.6 19.4 Allocetra n=27 Placebo n=25 Allocetra p - value = 0.0013 p - value = 0.0121 p - value = 0.0004 Placebo Note: baseline demographics & characteristics were well - balanced Results are normalized to 0 - 100 scale 22 | WOMAC total change 6 months, Primary OA population WOMAC pain change, 6 months Age ≥ 60 (52% of patients) Avg: - 24.9 18.9 Avg: - 16.8 21.1 Positive effect difference : 48% Allocetra n=31 Placebo n=32 Age ≥ 65 (31% of patients) Avg: - 26.3 14.1 Avg: - 9.5 15.3 Positive effect difference : 177% Allocetra n=21 Placebo n=17 Age ≥ 63 (39% of patients) Positive effect difference : 151% Avg: - 24.6 15.1 Avg: - 9.8 21.5 Allocetra n=25 Placebo n=22 ALLOCETRA EFFECT IN PRIMARY OA: CLINICALLY MEANINGFUL, STATISTICALLY SIGNIFICANT, TRENDING WITH AGE (REDUCTION IN PAIN & STIFFNESS, AND INCREASE IN FUNCTION) Allocetra p - value = 0.0085 p - value = 0.1132 p - value = 0.0012 Placebo Note: baseline demographics & characteristics were well - balanced Results are normalized to 0 - 100 scale 23 |

CLINICALLY MEANINGFUL, STATISTICALLY SIGNIFICANT POSITIVE EFFECT, HIGHLY CORRELATED WITH PRIMARY OA AGE THRESHOLD Change from baseline - 6 months Change from baseline - 3 months Age cutoff p - value % Better than placebo Difference Placebo Mean (SD) Allocetra Mean (SD) p - value % Better than placebo Difference Placebo Mean (SD) Allocetra Mean (SD) 0.0927 52% - 8.7 - 16.6 ( ц 21.6) - 25.3 ( ц 18.6) 0.0083 99% - 13.3 - 13.4 ( ц 20.6) - 26.8 ( ц 20.0) ≥ 60 0.0215 80% - 12.3 - 15.5 ( ц 21.0) - 27.8 ( ц 18.3) 0.0024 130% - 16.0 - 12.3 ( ц 19.6) - 28.2 ( ц 20.7) ≥ 61 0.0095 116% - 14.9 - 12.9 ( ц 21.9) - 27.8 ( ц 18.3) 0.0005 210% - 19.1 - 9.1 ( ц 19.4) - 28.2 ( ц 20.7) ≥ 62 0.0076 156% - 15.2 - 9.7 ( ц 22.3) - 24.9 ( ц 14.6) 0.0010 250% - 18.4 - 7.4 ( ц 19.6) - 25.8 ( ц 18.6) ≥ 63 0.0013 235% - 18.6 - 7.9 ( ц 21.1) - 26.5 ( ц 13.4) 0.0008 255% - 18.9 - 7.4 ( ц 20.0) - 26.3 ( ц 16.5) ≥ 64 0.0009 175% - 16.9 - 9.6 ( ц 15.1) - 26.5 ( ц 13.8) 0.0003 379% - 21.6 - 5.7 ( ц 19.2) - 27.3 ( ц 16.2) ≥ 65 The positive effect of Allocetra TM on pain & function is substantial, with at least 6 - month durability Trending with age 24 | Results are normalized to 0 - 100 scale SAFETY PROFILE: ALLOCETRA TM DEMONSTRATED A FAVORABLE SAFETY PROFILE, NO RELATED SERIOUS ADVERSE EVENTS WERE REPORTED • As observed also in earlier clinical data in severe OA subjects, some patients injected with Allocetra experienced local responses following injection (84% of patients treated with Allocetra , vs. 36% for placebo) • Local responses mostly involved some knee pain or discomfort (73% of patients treated with Allocetra , vs. 79% for placebo), and might have included knee swelling or limitation in range of motion (79% of patients treated with Allocetra , vs. 33% for placebo) • The events usually presented within 1 - 2 days following injection (average 1 day), and were mostly mild to moderate (93% of events), and transient (average duration 6 days, similar to placebo) • Patients were advised of the possibility of such reactions to occur, and guided that symptoms may be alleviated with rest, ice packs on the knee, compression bandages, and knee elevation. If needed, they were allowed to take NSAIDs for a few days • Overall, patients’ willingness to continue with treatments was minimally impacted by the side effects, only 7.5% of patients treated with Allocetra opted to discontinue subsequent injections due to adverse events 25 |

• Study objectives met • Allocetra TM demonstrated an encouraging safety profile, no related serious adverse events were reported • In primary age - related osteoarthritis patients, Allocetra TM treatment resulted in substantial, clinically meaningful, and durable effect, with high statistical significance of established Phase III endpoints, as well as multiple secondary endpoints ▪ Positive effect vs placebo exceeds FDA’s effectiveness thresholds required for commercial approval ▪ Robust and consistent effect, aligned with the proposed MOA of Allocetra • Osteoarthritis: a growing market with significant potential and unmet medical need with Primary OA responders representing more than ~50% 1 of the ~$7BN KOA market • Simple manufacturing process, highly attractive KOA treatment cycle at estimated total COGS (3 injections) of ~$450, allowing competitive pricing well within the range of high - end solutions • We believe Allocetra has strong potential to become the therapy of choice for primary knee osteoarthritis patients 1 Chen et al., Global burden of knee osteoarthritis from 1990 to 2021, PLoS One 2025 26 | DATA SUMMARY: 3 AND 6 - MONTH TOPLINE DATA – ENX - CL - 05 - 001 Patient criteria • Primary OA patients with symptomatic moderate to severe knee OA who have failed to respond to conventional OA therapy; • Age 60/65 - 80 years; • Kellgren - Lawrence (K - L) Grade 2 or 3.

NRS=numerical rating scale. WOMAC= Standard knee questionnaire evaluating pain, stiffness & physical function NEXT STEP: INITIATE ENX - CL - 05 - 002, a PHASE IIb in primary KOA patients Randomized, double - blind, placebo - controlled, multi - country study Phase IIb: Randomized, double - blind, placebo - controlled Allocetra TM (1 or 2 doses) vs. Placebo , 3 injections in total, each injection 2 weeks from the previous injection Endpoints: Primary: 3 - month change in WOMAC pain OR 3 - month change in WOMAC pain & function 27 | Safety and tolerability Secondary: 3 & 6 - month change in WOMAC total, NRS pain, and response assessments EXTENSIVE IP PROTECTION Australia Canada China France Germany Israel Japan United Kingdom 11 Patents USA 22 Patents Expected protection up to 2043 28 | Nasdaq: ENLV

CLINICAL INVESTMENT SUMMARY Management team with a track record of creating shareholder value and getting drug products through marketing approvals globally in multi - billion dollar market segments Cost - effective, novel therapeutic modality with strong IP protection Targeted at high and low grade inflammation in multi - billion dollar segments with poor treatment alternatives Platform for multiple indications. Allocetra can be infused systemically or locally to treat various diseases Simple, scalable, and cost - effective manufacturing process resulting in an off - the - shelf cell therapy Favorable safety profile demonstrated across 200+ patients Clinical data supportive of proposed MOA Clinically meaningful and statistically significant results in age - related knee osteoarthritis supporting late - stage development 29 | Nasdaq: ENLV

THANK YOU